New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
08:07 EDTADXSAdvaxis announces ADXS-HPV publication or preclinical research
Advaxis announced the publication of preclinical research with its lead candidate, ADXS-HPV for the treatment of HPV-associated cancers in the journal, Cancer Immunology Research. In this publication, researchers at the National Cancer Institute reported on the biologic mechanisms behind the unique ability of ADXS-HPV to decrease the immunosuppressive activity of Tregs in the tumor microenvironment that result in increased anti-tumor activity. This research demonstrates the critical role of the tLLO peptide fusion and the strong adjuvant effect of tLLO as contributing to the increase in activated T-cells and the relative decrease in the number of Tregs in tumors, thereby increasing anti-tumor activity. The company said, "The results are better than those achieved in earlier studies with different Lm-based immunotherapies. They suggest that tLLO serves as a promising adjuvant and that its incorporation into ADXS-HPV is a critical contributor to the changes in the tumor microenvironment that favor immune killing of the tumor cells." ADXS-HPV is in clinical trials for three HPV-associated cancers. Advaxis reported final Phase 2 data in recurrent cervical cancer at the 2014 American Society of Clinical Oncology Annual Meeting and plans to move forward with a registration program in recurrent cervical cancer.
News For ADXS From The Last 14 Days
Check below for free stories on ADXS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
07:48 EDTADXSAdvaxis, University of Pennsylvania restructure license agreement
Subscribe for More Information
July 28, 2014
07:38 EDTADXSAdvaxis receives patent in Japan
Advaxis announced that it has received a notice of allowance from the Japan Patent Office for a patent application related to the Advaxis proprietary Lm-LLO cancer immunotherapy platform technology. Once issued, this patent will provide protection in Japan until 2029. The claims under the patent cover composition of matter and methods of use for combining Advaxis's proprietary immunogenic, recombinant tLLO fused to full and partial antigens of particular interest to target cancers such as cervical, ovarian, melanoma, lung, and head and neck. The antigens covered under the claims include HPV-related and prostate cancer antigens, which are expressed in cervical and prostate cancer. Several of these claims are already patented in the United States. This patent along with the other issued patents in Japan, provides stronger protection for current and future uses of Advaxis immunotherapies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use